Apellis Pharmaceuticals, Inc. (APLS) Tops Q4 EPS by 85c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q4 EPS of $0.47, $0.85 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $199.91 million versus the consensus estimate of $198.82 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
• Citigroup set to join top banks in Anthropic IPO - Bloomberg
• Holcim to acquire Fermacell from James Hardie for EUR 840M